Compare ADMA Biologics Inc (ADMA) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Materials Select Sector SPDR Fund — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Materials Select Sector SPDR Fund trades at $50.3. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | XLB | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $53.62 |
52-Week Low | $7.60 | $42.23 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
XLB, the State Street Materials Select Sector SPDR ETF, trades at $51.98, down slightly by 0.06% today. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. The ETF, which provides broad exposure to the U.S. materials sector, lacks disclosed fundamental ratios like P/E and P/S in the provided data. Recent news highlights sector interest, with family offices investing $4.8 billion in materials as of May 23, 2026 (Barron's).
The outlook for XLB is supported by sector rotation into materials amid geopolitical shifts and earnings growth potential, but risks include sensitivity to macroeconomic factors and inflation. Analyst sentiment is mixed, with some viewing valuations as less compelling after recent gains. The ETF's performance will hinge on broader industrial and economic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
